logo
Plus   Neg
Share
Email

Reata Shares Jump 35% After Neuromuscular Disorder Drug Study Meets Endpoint

Shares of Reata Pharmaceuticals Inc. (RETA) jumped 35% after hours Monday after the biotech company announced positive results from a clinical trial for a neuromuscular disorder treatment.

Reata said the registrational Part 2 portion of the MOXIe Phase 2 trial of omaveloxolone in patients with Friedreich's ataxia met its primary endpoint of change in the modified Friedreich's Ataxia Rating Scale relative to placebo after 48 weeks of treatment.

Patients treated with omaveloxolone showed significant, placebo-corrected improvement in mFARS after 48 weeks of treatment, the company said.

"The results of MOXIe represent a truly historic moment for the patients, families, and caregivers that comprise the Friedreich's ataxia community," said Ronald Bartek, President of the Friedreich's Ataxia Research Alliance (FARA).

Friedreich's ataxia is a debilitating and degenerative neuromuscular disease that results in loss of coordination, muscle weakness and fatigue and can ultimately lead to death. There are currently no treatments approved by the Food and Drug Administration for the disease. It affects about 22,000 globally, the company said.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Panera Bread Co. is launching a new subscription program that will allow customers to drink unlimited coffee and tea. The new program of $8.99 per month launches Thursday and covers hot coffee, iced coffee and hot tea. With the introduction of the subscription, Panera becomes the first national restaurant company to offer unlimited hot drip coffee, iced coffee and hot tea for $8.99 per month. Best Buy Co. Inc. (BBY) Thursday reported a fourth-quarter profit that increased 1.4 percent from last year, while, J. C. Penney Co.'s (JCP) quarterly profit dropped 64 percent. However, the results of the companies topped analysts' estimates. Safavieh LLC recalled about 760 units of Aura and Silas 3-Drawer Chests for possible serious tip-over and entrapment hazards that can result in death or injuries to children, the U.S. Consumer Product Safety Commission said in a statement. The company said the chests are unstable if they are not anchored to the wall.
Follow RTT
>